Stockwinners Market Radar for November 28, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:05 EST Starbucks exec Conway sells 15,320 common shares - In a regulatory filing, Starbucks International group president Michael Aaron Conway disclosed the sale of 15,320 common shares of the company on November 23 at a price of $99.139 per share.

18:29 EST Faraday Future names Xuefeng Chen global CEO - Faraday Future Intelligent Electric announced that the FFIE Board of Directors has appointed FF China CEO Xuefeng Chen as Global CEO of Faraday Future, effective immediately. Chen replaces Carsten Breitfeld, who was removed as Global CEO by the FFIE Board of Directors following a comprehensive evaluation of the Company's performance since it went public in July 2021. Pursuant to the Company's Corporate Governance Guidelines, management directors are required to tender their resignation from the Board upon their removal as an officer of the Company. The Board has requested that Mr. Breitfeld tender his resignation from the Board in accordance with such Corporate Governance Guidelines. As Global CEO, Chen is tasked with delivering the FF 91 Futurist to market, delivering on the promise made to FF stockholders, investors, global partners, users and employees. "I believe the decision to appoint XF at this critical juncture of the Company is a timely and correct one," said FFIE Chairman of the Board of Directors Adam He. "XF is a top talent in the global automotive industry and possesses both a global perspective and extensive hands-on experience across the global automotive industrial chain. His years of experience at Ford and Jaguar Land Rover will pave a solid foundation for his leadership of Faraday Future's global team. The Company's top priority right now is to deliver the FF 91 Futurist to our users with high quality and minimal cost, and to successfully realize the US-China dual home market strategy with the ultimate goal to maximize Faraday Future stockholder interest," added He.

17:53 EST GE Healthcare, MediView partner over AR solutions for medical imaging - GE Healthcare and MediView XR announced their collaboration to integrate medical imaging into mixed reality solutions through the development of the OmnifyXR Interventional Suite System. MediView's current technology platform leverages spatial computing and mixed reality, united with medical imaging in combining augmented reality visualization, seamless remote collaboration and evidence-based clinical insights. "We are thrilled to advance our strategic collaboration with GE Healthcare by co-developing and creating the interventional suite of the future - one that is designed to improve ergonomics, with natural interactions for optimized workflow and facilitates care team collaboration. The physician is empowered to simultaneously interface with virtual monitors, holographic 3D anatomy, and remotely collaborate with colleagues around the world," said Mina Fahim, President and CEO of MediView. "Utilizing GE Healthcare's exceptional imaging and MediView's expertise in real-time augmented reality visualization and navigation, we're proud to together launch one of the largest deployments of augmented reality in healthcare to-date and grow clinical adoption of innovative extended reality solutions." GE Healthcare and MediView will co-market the solution and will explore opportunities for joint go-to-market efforts, with an initial market launch in the US and global expansion planned for the future.

17:20 EST Sabre to replace Flagstar Bancorp in the S&P 600 at open on 12/1 - Nexstar Media Group (NXST) will replace Sabre Corp. (SABR) in the S&P MidCap 400, and Sabre will replace Flagstar Bancorp (FBC) in the S&P SmallCap 600. S&P MidCap 400 constituent New York Community Bancorp (NYCB) is acquiring Flagstar Bancorp in a deal expected to be completed soon pending final conditions. Sabre has a market capitalization more representative of the small-cap market space.

17:17 EST Raytheon Technologies awarded $397.68M Navy contract modification - Raytheon was awarded a $397.68M firm-fixed-price modification to a previously awarded contract to exercise options for FY23 guided missile assemblies, shipping containers, and spare parts in support of the FY21-FY23 Evolved Seasparrow Missile Block 2 full-rate production requirements. Work is expected to be completed by March 2027. FY23 other customer funds in the amount of $214.45M; FY23 weapon procurement funds in the amount of $163.32M; FY20 other customer funds in the amount of $8.75M; FY21 other customer funds in the amount of $7.23M; FY19 other customer funds in the amount of $1.31M; FY22 other customer funds in the amount of $1.25M; FY22 weapons procurement funds in the amount of $824.92M and FY21 weapons procurement funds in the amount of $538,000, will be obligated at time of award and $538,000 will expire at the end of the current fiscal year. The Naval Sea Systems Command is the contracting activity.

17:00 EST Ichor Holdings names Bruce Ragsdale COO - Ichor Holdings announced the appointment of Bruce Ragsdale as the company's new chief operating officer, effective December 12, 2022. Ragsdale will be responsible for overseeing Ichor's global operations and supply chain. "We are very pleased to welcome Bruce Ragsdale to Ichor as our new COO," said Jeff Andreson, CEO. "Bruce brings nearly 30 years of manufacturing, engineering, and supply chain experience in the semiconductor capital equipment industry. He has a stellar track record of operational excellence at both Applied Materials and ASM International, and has a wealth of experience around the globe that will enable him to make valuable contributions toward the execution of our operational and financial objectives." Ragsdale most recently served as vice president, supply chain sourcing at Intel Corporation.

16:55 EST CNS Pharmaceuticals announces 1-for-30 reverse stock split - CNS Pharmaceuticals announced a 1-for-30 reverse split of its common stock, effective at 4:01 PM ET Monday. Beginning on November 29, 2022, the company's common stock will continue to trade on The Nasdaq Capital Market on a split adjusted basis under the trading symbol "CNSP", but will trade under the following new CUSIP number: 18978H201. The reverse stock split was approved by CNS Pharmaceuticals' stockholders at the 2022 annual meeting of stockholders. The reverse stock split is primarily intended to increase the company's per share trading price and bring the Company into compliance with the Nasdaq's listing requirement regarding minimum share price.

16:36 EST Alpha Metallurgical sees FY23 total shipments 16.7M-18.4M tons - Alpha Metallurgical announced its operational guidance for the 2023 calendar year. The FY23 guidance introduced by the company includes an increase in shipments from 2022 levels, with 15M to 16M metallurgical tons expected to account for the majority of the company's total shipments of 16.7M to 18.4M tons. In terms of expected cost of coal sales, Alpha is guiding to a range of $106.00 to $112.00 per ton in the Met segment and a range of $87.00 to $93.00 per ton in the All Other category. These ranges reflect an expectation of continued inflationary pressure through the 2023 calendar year, most notably in the areas of labor and supplies. The company is issuing guidance for selling, general and administrative costs in a range of $59 million to $65 million for 2023, excluding non-recurring expenses and non-cash stock compensation. Idle operations expense is expected to be between $21 million and $31 million. Cash interest expense is projected in a range of $2 million to $10 million, and depreciation, depletion and amortization are anticipated to be between $115 million to $135 million. Capital expenditures are expected to be between $250 million and $280 million for the full year, which includes some carryover from 2022, sustaining maintenance capital, and several planned projects to invest in mine development, equipment, and portfolio enhancements. The company expects a tax rate of between 15% to 20% for 2023. "As we continue working hard to safely wrap up a record-setting year of accomplishments, we are also looking forward to 2023 and what lies ahead for Alpha," said David Stetson, chair and chief executive officer. "I couldn't be prouder of our team's 2022 performance, which includes paying off our term-loan debt and capitalizing on market opportunities that allowed Alpha to set and subsequently break a new Adjusted EBITDA record in back-to-back quarters. Additionally, the company has returned over $500 million to shareholders through share repurchases and dividends. While market conditions unquestionably facilitated these achievements, our performance was also underpinned by focused decision-making and a commitment to strengthening the long-term health of the company. We expect 2023 to be a continuation of these efforts as we step up our production expectations and continue investing in our future success. As we mentioned in our most recent earnings call, we have experienced some challenges in obtaining the specialized contract labor and supplies for some of the projects that were included in 2022's capital expenditures budget," Eidson said. "Therefore, we are building in roughly $33.5 million of carryover capex to the coming year's guidance. We anticipate that our sustaining, or maintenance, capital needs will be just under $10.00 per ton for 2023, which, at the midpoint of our shipment guidance, equates to approximately $170 million for the year, which includes both supplemental and technologically advanced safety equipment. The balance of our projected capital spending in 2023 will be for development projects. These projects include development of new mines and enhancements to some of our existing properties to support our broader production and shipment goals for the upcoming year. We are excited about the opportunity to make meaningful investments that are expected to further strengthen the safety and longevity of the Alpha portfolio for many years to come."

16:30 EST Vail Resorts names Angela Korch CFO - Vail Resorts announced the appointment of Angela Korch as Executive Vice President and Chief Financial Officer, effective Dec. 22, 2022. Angela rejoins Vail Resorts from CorePower Yoga, where she served as Chief Financial Officer since May 2020, after previously spending more than a decade in successive leadership roles within Vail Resorts' finance organization, working closely with the company's current CFO, Michael Barkin. "We are pleased to welcome Angela back to Vail Resorts as our new CFO," said Chief Executive Officer of Vail Resorts, Kirsten Lynch. "Angela is a strong leader with deep experience in our industry, a passion for our sport, and a long history with our company." Korch will replace Barkin, who announced his resignation in July 2022 to pursue personal opportunities. Barkin has remained in role to support the transition to his successor. His last day will be Jan. 1, 2023.

16:29 EST Shell to acquire RNG producer Nature Energy for nearly $2B - Shell Petroleum NV, a wholly owned subsidiary of Shell plc, has reached an agreement with Davidson Kempner Capital Management LP, Pioneer Point Partners and Sampension to acquire 100% shareholding of Nature Energy Biogas A/S for nearly $2B. The acquisition will be absorbed within Shell's current capital range, which remains unchanged. Based in Denmark, Nature Energy is a producer of Renewable Natural Gas from agricultural, industrial, and household wastes. By purchasing the shares in Nature Energy, Shell will acquire the largest RNG producer in Europe, its portfolio of cash generative operating plants, associated feedstock supply and infrastructure, its pipeline of growth projects and its in-house expertise in the design, construction, and operation of innovative and differentiated RNG plant technology. The transaction is subject to regulatory approvals and is expected to close in Q1 2023. Nature Energy is cash generative, and the acquisition is expected to be both accretive to Shell's earnings from completion and deliver double digit returns.

16:15 EST Inventiva granted patent for lanifibranor by USPTO - Inventiva announced that the United States Patent and Trademark Office, or USPTO, granted a patent that protects the use of lanifibranor for the treatment of cirrhotic patients at risk of progressing from compensated stage to decompensated stage. This patent will expire on November 8, 2039. The company said, "This new patent further strengthens Inventiva's patent portfolio for lanifibranor, the company's lead product candidate, in the United States, which already comprised patents protecting the use of lanifibranor to treat several diseases including non-alcoholic steatohepatitis and fibrotic diseases. This patent further expands the intellectual property protection of lanifibranor in the United States for use in patients with cirrhotic NASH."

16:08 EST Red Cat enters stock purchase agreement to divest consumer business - Red Cat announced that it has entered into a stock purchase agreement with Unusual Machines for the purchase and sale of its consumer division consisting of Rotor Riot and Fat Shark Holdings, the company's recreational and hobbyist drones and first-person-view goggles subsidiaries. The SPA followed an internal review of the company's military and enterprise opportunities to focus the company's efforts on its Made in America Class 1 ISR Drone development program and the Company's Golden Eagle I, Golden Eagle II, Four Ship, and swarm software under development. Under terms of the stock purchase agreement, or SPA, and upon satisfaction of the requisite closing conditions, including shareholder approval, Unusual Machines will purchase Rotor Riot and Fat Shark Holdings from Red Cat for $18M in cash and securities of Unusual Machines. The purchase price will consist of $5M in cash, $2.5M in a convertible senior note of Unusual Machines, and $10.5M in Series A convertible preferred stock of Unusual, payable at closing. Both the convertible senior note and convertible preferred stock of Unusual Machines will be convertible into shares of Unusual Machines. In addition, closing of the SPA is subject to successful completion of an initial public offering by Unusual Machines in the minimum amount of $15M and approval by Nasdaq of listing of Unusual Machine's common stock.

16:06 EST Kala announces submission of IND for KPI-012 for PCED treatment - Kala Pharmaceuticals announced the submission of an investigational new drug IND application to the U.S. Food and Drug Administration for KPI-012 for the treatment of Persistent Corneal Epithelial Defect . Subject to acceptance of the IND by the FDA, Kala remains on-track to initiate a Phase 2b clinical trial of KPI-012 for PCED in the fourth quarter of 2022. Topline safety and efficacy data from the trial is expected in the first quarter of 2024. If positive, this trial could serve as the first of two pivotal trials needed to support the submission of a Biologics License Agreement (BLA) to the FDA. Following acceptance of the IND for KPI-012 by the FDA, Kala will receive the second tranche from the private placement of securities announced earlier today which, together with current cash on hand, Kala expects will extend its projected cash runway into the first quarter of 2025. "We are pleased to announce the submission of the IND for PCED, which brings us an important step closer to our goal of delivering the promise of mesenchymal stem cell secretome based therapies to address severe ocular diseases," said Mark Iwicki, Chief Executive Officer and Chairman of Kala Pharmaceuticals. "This accomplishment is well timed with the investment commitment announced earlier today from a life sciences-focused investor, which reflects a belief in the power of our MSC-S platform to address significant unmet needs across a range of rare ophthalmic diseases and, in particular, the potential for KPI-012 to become the first approved prescription therapy indicated for PCED patients with a broad range of underlying etiologies. We look forward to initiating this trial before year end."

15:57 EST Judge orders Amazon to cease firing staff for protected activities - The National Labor Relations Board said that on November 18, 2022, Judge Diane Gujarati of the United States District Court for the District of Eastern New York issued a Section 10(j) injunction against Amazon.com Services LLC directing Amazon to cease and desist from discharging employees, and from engaging in any like or related conduct, in retaliation for employees engaging in protected activities. The injunction also directs Amazon to post, distribute, and read the Court's order to employees at the Employer's Staten Island facility. The injunction was issued based on a petition for Section 10(j) injunctive relief filed by Kathy Drew King, former Regional Director of Region 29 of the NLRB. Section 10(j) of the National Labor Relations Act authorizes the NLRB to seek injunctions against employers and unions in federal district courts to ensure that employees' rights will be adequately protected from remedial failure due to the passage of time. The petition alleged that Amazon unlawfully fired an employee at JFK8 for advocating, with his co-workers, for workplace health and safety protections in light of the COVID-19 pandemic and by protesting with his co-workers Amazon's failure to provide greater safety protections to employees. While the injunction does not order interim reinstatement of the employee at this time, it does order Amazon to cease and desist from further discharging any employees for protected activities under the NLRA, or in any like or related manner interfering with, restraining, or coercing employees in the exercise of the rights guaranteed to them by Section 7 of the National Labor Relations Act. If Amazon violates the cease-and-desist order, it could be held in contempt by the court. "The Judge's order in this case recognizes Amazon's unlawful conduct and provides the full force of a federal court injunction to prohibit Amazon from further discharging employees for engaging in protected concerted activity," said Region 29 Brooklyn Director Teresa Poor. "This relief is critical to ensure that Amazon employees can fully and freely exercise their rights to join together and improve their working conditions, including by forming, assisting, or joining a union." Reference Link

15:11 EST Musk says Apple 'threatened to withhold Twitter' from App Store - Tesla (TSLA) CEO and founder Elon Musk tweeted: "Apple (AAPL) has also threatened to withhold Twitter (TWTR) from its App Store, but won't tell us why" Reference Link

14:21 EST California AG announces settlements against Google, iHeartMedia over radio ads - California Attorney General Rob Bonta, in partnership with the Federal Trade Commission and other state attorneys general, announced settlements against Google (GOOGL) and iHeartMedia (IHRT) resolving allegations that Google paid DJs, predominately at iHeartMedia, to offer misleading personal endorsements of the Google Pixel 4 cell phone, even though most had never used the phone. This conduct violated California's False Advertising Law and Unfair Competition Law. As part of the settlement, Google will pay $9 million, of which California will receive approximately $2.7 million, and iHeartMedia will pay $400,000, of which California will receive approximately $125,000. Both companies will also be required to comply with important injunctive terms to deter future misconduct. "In 2019, Google partnered with iHeartMedia and other local radio stations to run an ad campaign for the Google Pixel 4. In these ads, Google instructed radio personalities to describe their supposed personal experiences using the Pixel 4, despite the phone not yet being available, and despite Google refusing to provide the phones to any stations in advance of recording and airing the first-round ads. Therefore, the radio personalities' statements about their personal experience were generally untrue. Google ran these ads over 23,000 times in 10 different markets, including more than 9,000 times in the San Francisco and Los Angeles media markets," AG Rob Bonta's statement said. In addition to monetary penalties, Google and iHeartMedia will comply with injunctive terms to deter future misconduct. Google, specifically, will be subject to a 20-year injunction prohibiting it from making misrepresentations or encouraging misrepresentations when hiring endorsers to advertise its products. Google will also be required to submit compliance reports upon request and engage in robust record keeping to demonstrate full compliance with the settlement agreement. Attorney General Bonta joins the Federal Trade Commission and the attorneys general of Arizona, Georgia, Illinois, Massachusetts, and New York in the settlement against Google. Texas also joined the group in its settlement against iHeartMedia. Reference Link

12:57 EST Instil Bio treatment of stage IB2 to IV cervical cancer granted orphan status - Instil Bio's autologous cell therapy product manufactured from tumor-infiltrating lymphocytes has been granted FDA orphan designation as a treatment of stage IB2 to stage IV cervical cancer, according to a post to the agency's website. Reference Link

12:00 EST Grindr falls -11.1% - Grindr is down -11.1%, or -$1.06 to $8.49.

12:00 EST Energy Vault falls -14.5% - Energy Vault is down -14.5%, or -72c to $4.23.

12:00 EST LiveWire rises 8.8% - LiveWire is up 8.8%, or 51c to $6.31.

11:52 EST Avid Technology appoints Deb Sanders as CCO - Avid announced the promotion of Deb Sanders to the role of Chief Customer Officer & Senior Vice President to lead worldwide operations for customer success, customer care, advocacy, learning and overall CX, as well as oversee collaboration with the customer-led Avid Community Association. Sanders joined Avid as Vice President of Global Customer Care in 2019. Deb ascends to the executive leadership role previously held by Kathy-Anne McManus, former Chief Customer Experience Officer, who has left Avid to accept a new professional opportunity.

10:41 EST Theralink announces CAP accreditation for laboratory in Colorado - Earlier, Theralink Technologies announced that the company has received College of American Pathologists, or CAP, Accreditation for its Reverse Phase Protein Array laboratory in Golden, Colorado. The Accreditation Committee of the College of American Pathologists has awarded accreditation to the Theralink Technologies' laboratory based on results of a recent on-site inspection as part of its Accreditation review system. "This is a major milestone for Theralink, as we now have the only commercial Reverse Phase Protein Array laboratory in the United States with CAP accreditation for our Next Generation Proteomic services," said Mick Ruxin M.D., CEO of Theralink Technologies. "Theralink is now both CLIA-certified and CAP-accredited, demonstrating that our test results and laboratory processes are meeting and exceeding industry standards for clinical testing. CAP accreditation is the champion of laboratory excellence, and cancer patients will potentially benefit with our accreditation."

10:21 EST Cleveland-Cliffs announces price increase for steel products - Cleveland-Cliffs announced that it is increasing current spot market base prices for all carbon hot rolled, cold rolled and coated steel products by a minimum of $60 per ton, effective immediately with all new orders.

10:00 EST Talos Energy falls -6.1% - Talos Energy is down -6.1%, or -$1.24 to $19.11.

10:00 EST SilverBow Resources falls -6.6% - SilverBow Resources is down -6.6%, or -$2.34 to $33.35.

10:00 EST Shopify rises 8.8% - Shopify is up 8.8%, or $3.24 to $40.03.

09:49 EST Biocytogen enters antibody agreement with ADC Therapeutics - Biocytogen entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a license to evaluate Biocytogen's proprietary antibodies against three tumor targets, with an option to license selected antibodies at a later date for global ADC development and commercialization. Biocytogen reserves all global rights for these antibodies beyond ADC development. Biocytogen will receive an upfront payment. For each option exercised, Biocytogen will be entitled to an option-exercise fee, and development and commercial milestone payments, which potentially total tens of millions of US dollars, as well as single-digit royalties on net sales. Under the agreement, Biocytogen will provide ADC Therapeutics with monoclonal and/or biparatopic antibodies directed against three tumor targets, generated through Biocytogen's Project Integrum. ADC Therapeutics will carry out feasibility studies and be responsible for further development and commercialization of the ADC products if the company exercises an option.

09:47 EST Talos Energy falls -6.6% - Talos Energy is down -6.6%, or -$1.35 to $19.00.

09:47 EST KE Holdings rises 6.8% - KE Holdings is up 6.8%, or 97c to $15.26.

09:47 EST Arcus Biosciences rises 13.5% - Arcus Biosciences is up 13.5%, or $3.60 to $30.31.

09:38 EST Knightscope says existing client to upgrade 97 parking lot emergency call boxes - Knightscope announces that an existing transit client in California signed a contract to upgrade 97 of its parking lot emergency call boxes with the Knightscope K1 Retrofit Kits.

09:36 EST Modular Medical expects to make 510(k) submission during quarter ended June 30 - Modular Medical announced an update on the development of its initial insulin pump product. The Company has continued to make progress on the testing required for its 510(k) submission to the U.S. Food and Drug Administration of its MODD1 insulin pump product. The Company has identified certain material in the pump device that was incompatible with the sterilization process utilized. As previously announced, this compatibility issue has delayed the Company's 510(k) submission timeline. The Company has identified replacement materials, which are being qualified for use in the product. Given the expected resolution of the compatibility issue, the Company now expects to make its submission to the FDA during the quarter ended June 30, 2023.

09:27 EST Quest Diagnostics completes acquisition of LabCare - Quest Diagnostics announced it has completed its previously announced acquisition of select assets of LabCare Plus, the outreach laboratory services business of Summa Health, a large integrated health system. Additional financial terms were not disclosed. With the acquisition, Quest broadens access to diagnostic innovation and insights empowering better health for more communities in Northeastern Ohio. Physicians and patients will benefit from access to Quest's industry-leading and highly innovative test menu, network of patient access sites throughout the state, broad health plan coverage and lower out-of-pocket costs for many services.

09:24 EST Peraso announces $2.45M registered direct offering - Peraso announced that it has entered into a securities purchase agreement with an institutional investor in connection with a registered direct offering of an aggregate of 2,450,000 shares of its common stock. The pre-funded warrants will be immediately exercisable at a nominal exercise price of $0.01 per share and may be exercised at any time until all of the pre-funded warrants are exercised in full. Additionally, in a concurrent private placement, the Company will issue to the Investor unregistered common stock purchase warrants to purchase up to 3,675,000 shares of common stock. The Private Placement Warrants have an exercise price of $1.36 per share and are exercisable for a period of five years beginning six months from the date of issuance. The Benchmark Company, LLC is acting as the sole placement agent for the offering. The gross proceeds from the registered direct offering and concurrent private placement are expected to be $2.45 million before deducting placement agent fees and other estimated offering expenses. Peraso intends to use the net proceeds from this offering for the Company's operations, including the development of its 5G products, and working capital and general corporate purposes. The registered direct offering and concurrent private placement are expected to close on or about November 30, 2022, subject to the satisfaction of customary closing conditions.

09:21 EST Performance Shipping announces loan facility with Piraeus Bank - Performance Shipping announced that it has entered into an agreement for a secured term loan facility of up to $37.4 million with Piraeus Bank S.A. through two separate wholly-owned subsidiaries of the Company. Proceeds from the Facility will be used to refinance a portion of an existing term loan facility for the M/T P. Kikuma through a first advance of up to about $7.8 million and to partially finance the M/T P. Monterey, through a second advance of up to about $29.6 million. This Facility will carry an interest rate of SOFR plus 2.45% per annum and will be repayable in twenty consecutive quarterly installments. The first four installments will be equal to US$1.5 million each, the remaining sixteen installments will be equal to $1 million each, and a balloon installment of US$15.4 million will be payable concurrent with the twentieth quarterly installment, within five years from the drawdown date. The Facility is secured by, among other things, a guarantee of the Company and first priority mortgages over the M/T P. Kikuma and M/T P. Monterey.

09:20 EST BlackBerry expands work with AWS to elevate BlackBerry QNX software to cloud - BlackBerry Limited announced an extension of its use of Amazon Web Services, AWS, that will make BlackBerry QNX technology available to embedded systems developers for the first time ever in the cloud, significantly reducing time to market for their products. At AWS re:Invent 2022, BlackBerry QNX will demonstrate the company's Real Time Operating System along with its artificial intelligence data platform - BlackBerry IVY - running natively on Amazon Elastic Compute Cloud instances, powered by AWS Graviton2 processors. The BlackBerry QNX RTOS running in the cloud functions as a cloud-native developer workbench and can be used independently - or in conjunction with - BlackBerry IVY, a cloud connected automotive AI platform co-developed by BlackBerry and AWS

09:17 EST Hempacco, High Sierra enter joint venture agreement - On November 17, 2022, the Company's wholly-owned subsidiary, High Sierra Technologies, Inc., a Nevada corporation executed a Joint Venture Agreement with Hempacco Co., for the production, marketing, and sales of hemp smokables that will use the Company's patented and patent-pending technologies, as well as certain patented and patent-pending technologies held by Hempacco. Pursuant to this Joint Venture Agreement, HSTI and Hempacco formed a new Nevada corporation known as Organipure. HSTI and Hempacco each own one-half of the equity interests in Organipure. In connection with the execution of the Joint Venture Agreement, Hempacco also entered a Hemp Smokables Manufacturing Agreement with Organipure, pursuant to which Hempacco will act as Organipure's exclusive worldwide manufacturer and supplier of hemp smokables, subject to the terms and conditions of the Manufacturing Agreement. The hemp smokables will be manufactured according to product specifications and packaging described in the Manufacturing Agreement. Also, in connection with the execution of the Joint Venture Agreement, HSTI entered into a Patent License Agreement with Organipure, which granted Organipure a non-exclusive license of HSTI's patented and patent-pending technologies to be used in connection with the hemp smokable products to be produced, marketed, and sold by Organipure. The annual license fee will be 5% of Organipure's gross receipts from the use of the HSTI patents by Organipure. The term of the license expires December 31, 2033, unless terminated earlier for reasons specified in the HSTI Patent License Agreement. Similarly, Hempacco entered into a Patent License Agreement with Organipure which granted to Organipure a non-exclusive license of Hempacco's patented and patent pending technologies to be used in connection with the hemp smokable products. The annual license fee will be 5% of Organipure's gross receipts from the use of the Hempacco patents by Organipure. The term of the license expires December 31, 2033, unless terminated earlier for reasons specified in the Hempacco Patent License Agreement.

09:12 EST Fortinet launches FortiGate Cloud-Native Firewall - Fortinet announced the availability of FortiGate Cloud-Native Firewall on Amazon Web Services, an enterprise-grade, managed next-generation firewall service specifically designed for AWS environments. FortiGate CNF incorporates FortiGuard artificial intelligence -powered Security Services for real-time detection of and protection against malicious external and internal threats, and is underpinned by FortiOS for a consistent network security experience across AWS and on-prem environments. By shifting the management of network security infrastructure to Fortinet via FortiGate CNF, customers can focus more on their core competencies and deploying effective security policies to protect their business-critical applications and data. Natively supporting AWS and available now in AWS Marketplace, FortiGate CNF gives customers immediate access to FortiGuard AI-powered Security Services for enterprise-grade protection, including URL filtering, DNS filtering, IPS, application control and other FortiGuard security services, that organizations rely on.

09:10 EST Diebold appoints Radigan as executive vice president, chief people officer - Diebold Nixdorf announced that Elizabeth Radigan has been appointed as executive vice president and chief people officer. She replaces Beth Patrick, who is pursuing other interests outside the company. Radigan, who previously held the role of Diebold Nixdorf's chief ethics and compliance officer since joining the company in 2014, will lead the company's global employee-focused initiatives, promoting a strong workforce of engaged employees and driving effective processes that support and equip employees worldwide. Radigan will also serve as a member of the company's senior executive leadership team. She reports to Octavio Marquez, Diebold Nixdorf president and chief executive officer.

09:09 EST Arthur J. Gallagher acquires Bulen & Associates Insurance Services - Arthur J. Gallagher & Co. announced the acquisition of Murrieta, California-based Bulen & Associates Insurance Services. Terms of the transaction were not disclosed. "Bulen & Associates is a highly regarded agency with deep community roots and a culture like ours," said J. Patrick Gallagher, Jr., Chairman, President and CEO. "I am delighted to welcome Lisa and her associates to Gallagher."

09:08 EST Hagerty opens Garage + Social Van Nuys, partners with Long , Emory - Hagerty (HGTY) announces the opening of Garage + Social Van Nuys, the latest in its growing, national network of enthusiast facilities. Porsche (POAHY) factory racing driver Patrick Long and longtime Porsche restorer Rod Emory, both with Southern California roots, have partnered with Hagerty to launch the new location, which will offer a premium clubhouse and storage facility for Los Angeles area car lovers and collectors. "One of the great things about the car world is that we love to gather, share stories and revel in our shared passion and appreciation of collectible cars," said Hagerty CEO McKeel Hagerty. "Patrick and Rod's extensive careers, gracious personalities and SoCal roots mean that they'll create a great atmosphere for Garage + Social members. The result will be an oasis for car enthusiasts, designed by car enthusiasts. It's a place where members and the public alike will enjoy truly special moments that perfectly complement Hagerty's purpose to save driving and car culture for future generations."

09:06 EST Couchbase selected by Arthrex to improve patient outcomes - Couchbase announced that Arthrex selected Couchbase on Amazon Web Services to improve patient outcomes. Embedded in the Arthrex Synergy product family, Couchbase is used in customer hospitals and operating rooms to manage the capture, sync and storage of patient data, surgical data and media metadata, including captured images and videos from Arthrex devices. Arthrex is a global leader in orthopedics providing interconnected surgical devices for hospital operating rooms, such as endoscopic cameras, pumps, ablation devices and insufflators--devices that surgeons use for bone and ligament surgery and reconstruction. The devices run a Linux-based application with Couchbase Lite embedded to store relevant data, allowing them to run 100% of the time regardless of internet connectivity and speed. This reduces latency and downtime for critical surgical instruments. Once data is in a centralized location in the hospital, it powers Arthrex's suite of applications that connect to surgical devices and other medical systems, including hospital electronic health record systems.

09:04 EST EVCI Career Colleges announces YTD results of Dashang - EVCI Career Colleges Holding previously announced a change of control with Zhejiang Dashang Media Co., Ltd. in which Zhejiang Dashang Media Co., Ltd. acquired controlling interest in a private transaction through all outstanding classes of preferred shares. Gross revenues of $61.6 million for the year to date, up 300% versus annualized 2021 revenue ; 1.7 million users, up approximately 100% versus 2021 ; 401,755 daily users, up approximately 80% versus 2021; 33,871 daily paying users, up approximately 80% versus 2021. "We are excited about the growth with Dashang Short Video and what that means for value for EVCI shareholders" stated Wei Li, Chairman. "I believe 2023 could be a record year and we are projecting significant growth". EVCI Career Colleges Holding Corp. plans to submit a name and symbol change to FINRA in the coming weeks to mirror the company's new business model. The company plans to report on its strategy for growth as well as acquisitions lined up for 2023 in the coming months.

09:03 EST AIkido Pharma announces successful initial public offering of ASP Isotopes - AIkido Pharma announced the successful initial public offering of ASP Isotopes. ASPI priced its initial public offering of 1,250,000 shares of its common stock at a public offering price of $4.00 per share, for aggregate gross proceeds of approximately $5.0 million before deducting underwriting discounts, commissions, and other offering expenses. The shares began trading on the Nasdaq Capital Market LLC on Nov. 10, 2022, under the ticker symbol "ASPI", and the offering closed on about Nov. 14, 2022. Anthony Hayes, CEO of AIkido stated, "As a shareholder of ASP Isotopes, we want to congratulate the company and their CEO, Paul Mann on successfully listing on NASDAQ. This has been one of the most challenging public markets in recent memory for new issuers. We congratulate Paul and his team for getting this public offering over the line. As a public company, ASP will benefit from access to capital, broader investor outreach and engagement, and greater visibility for its customers and partners. We hope to have other companies where we are a shareholder to follow ASPI's lead in the near future.

08:59 EST Gilead, Arcus provide update from fourth interim analysis of ARC-7 study - Gilead (GILD) and Arcus Biosciences (RCUS) announced an update from the fourth interim analysis of the randomized, open-label Phase 2 ARC-7 study in patients with first-line metastatic non-small cell lung cancer, or NSCLC, with PD-L1 tumor proportion score of 50% without epidermal growth factor receptor or anaplastic lymphoma kinase mutations. ARC-7 is evaluating the combinations of anti-TIGIT antibody domvanalimab plus anti-PD-1 antibody zimberelimab and domvanalimab plus zimberelimab and etrumadenant, an A2a/b adenosine receptor antagonist, versus zimberelimab alone, and represents the first randomized Phase 2 study of an Fc-silent anti-TIGIT/anti-PD-1 combination. The protocol-specified fourth interim analysis was conducted when the trial reached full enrollment, with a clinical data cutoff date of August 31. A total of 150 patients have been randomized across the three study arms. For the current interim analysis, efficacy was evaluated in study patients who had at least 13 weeks of potential follow-up and were eligible for at least two imaging scans. Both domvanalimab combinations continued to show clinically meaningful differentiation compared to zimberelimab monotherapy across multiple efficacy measures, including objective response rates, progression-free survival and six-month landmark PFS. Detailed results from this fourth interim analysis and an exploratory analysis on 12 patients who crossed over from zimberelimab monotherapy arm to triplet therapy will be presented on December 20, 2022, at the Monthly Plenary Series, a new virtual forum for presentation and discussion of the latest cancer research. According to ASCO, live presentations are accessible to virtual attendees and available on-demand, and abstract presentations are accompanied by a discussant presentation and followed by a live Q&A session. Abstracts accepted for the Monthly Plenary Session are also placed at the ASCO Annual Meeting in June 2023. During the ASCO Annual Meeting, additional results from further analysis of the ARC-7 dataset will be presented. Domvanalimab, zimberelimab and etrumadenant are investigational molecules and neither Arcus or Gilead have received approval from any regulatory authority for any use globally, including for the treatment of lung cancer. Their efficacy and safety for the treatment of lung cancer have not been established.

08:56 EST Vinco Ventures receives deficiency notice from Nasdaq - On November 17, 2022, Vinco Ventures received a notice from the Listing Qualifications Department of The Nasdaq Stock Market advising the Company that it was not in compliance with Nasdaq's continued listing requirements under the Nasdaq Listing Rule 5250(c)(1) as a result of the Company's failure to file its Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 with the United States Securities and Exchange Commission in a timely manner, which deadline was November 14, 2022. The Rule requires listed companies to timely file all required periodic reports with the SEC. As a result of a delinquency notice received with respect to the Company's as yet filed 10-Q for the quarter ended June 30, 2022, the Company has submitted a plan of compliance to file both delinquent 10-Qs no later than January 30, 2023. The Company will submit an update to this plan of compliance to Nasdaq no later than December 19, 2022 confirming the above referenced timetable.

08:52 EST Maine Beer Company installs Chart Industries' Earthy Labs CO2 capture technology - Maine Beer Company is among the first craft breweries in Maine to implement Chart Industries' Earthly Labs' carbon capture technology to reduce greenhouse gas emissions. Earthly Labs CiCi technology allows Maine Beer Company to capture waste carbon dioxide produced during fermentation, purify it and reuse it to carbonate the beer, purge tanks and package beer.

08:49 EST United Health to submit full PMA application following sample analysis review - United Health Products provides an update on the company's FDA Premarket Approval application. UHP continues to advance its Premarket Approval application with the Food and Drug Administration. As described in its October 31 press release, the company has completed its review and documentation of manufacturing and packaging related Standard Operating Procedures and is now awaiting external laboratory test results on HemoStyp samples produced under its new manufacturing arrangement. Upon receipt and review of the sample analysis, the company expects to submit its full PMA application within a few days. There can be no assurance that the company's PMA application will be approved.

08:46 EST Jeffs' Brands says 2022 Black Friday sales increased 60% year-over-year - Jeffs' Brands announced that its brands' sales on Amazon on November 25, 2022, known as Black Friday, the day after the Thanksgiving holiday. Total estimated revenues generated by its brands on that date were approximately $190,000, an increase of approximately 60% compared to approximately $118,055 in 2021 Black Friday sales.

08:44 EST Poet Technologies enters agreement with Stockhouse Publishing - POET Technologies announced that it has signed an agreement with Stockhouse Publishing, Ltd., a division of The Market Herald. The agreement covers a 12-month period during which POET will use a variety of new tools and services offered by Stockhouse to drive large scale investor awareness about the company. POET will continue to use social media and internet marketing to distribute existing and newly created content to targeted audiences in Canada, the US and Europe. The Company will pay C$100,000 against which it will choose from a menu of standard and custom advertising and marketing campaigns over the year to reach targeted investor audiences. In July of this year, the Company terminated its agreement with North Equities.

08:41 EST Qorvo partners with MediaTek to secure design wins - Qorvo secured multiple design wins in collaboration with MediaTek that extend Qorvo's leadership in 5G smartphones and include mobile Wi-Fi, Wi-Fi routers, and 5G/Wi-Fi automotive platforms.The automotive design wins are with tier 1 suppliers and will enable 5G connectivity in 2023 automotive platforms. Qorvo's 5G automotive solutions are optimized with MediaTek to support enhanced safety and entertainment features including telematics, advanced driver-assistance systems, autonomous driving, emergency calling and in-vehicle connectivity and entertainment services. Qorvo's automotive connectivity portfolio enables complete AECQ-qualified connectivity solutions - from onboard telematics to the shark fin antenna. Qorvo has also secured Wi-Fi 6, Wi-Fi 6E and Wi-Fi 7 design wins in a range of devices including service provider gateways and smartphones. Qorvo mates its advanced filters and Wi-Fi integrated front end modules with MediaTek Wi-Fi systems-on-chip to deliver end-to-end Wi-Fi solutions that increase throughput, reduce latency and enhance the quality of client connections. In smartphones, Qorvo has secured multiple design wins with leading OEMs that span Qorvo's broad portfolio of highly integrated advanced cellular solutions. The global smartphone market is supported by multiyear content and integration trends, with outsized opportunities among MediaTek customers as Android OEMs migrate their portfolios to higher performing 5G devices.

08:38 EST Enlivex Therapeutics receives FDA clearance for Allocetra IND - Enlivex Therapeutics announced that the U.S. Food & Drug Administration has cleared an Investigational New Drug application to study Allocetra in patients with advanced solid malignancies. The FDA's Phase I/II clearance follows a recent announcement by the Company that the first patient has been dosed in a Phase I/II multi-center clinical trial in Israel designed to evaluate the safety, tolerability and preliminary efficacy of Allocetra stand-alone, and in combination with a PD1 checkpoint inhibitor, in patients with advanced solid tumors.

08:37 EST Reliance Global enters referral partnership with Eastern Union - Reliance Global Group announced that it has entered into a referral partnership with Eastern Union Funding. Under the agreement, RELI Exchange agency partners will now be able to refer clients to Eastern Union for commercial real estate financing, including multi-family and commercial structures.

08:36 EST Hain Celestial appoints Wendy Davidson as president, CEO - The Hain Celestial Group announced a leadership succession plan, naming Wendy Davidson as President and CEO, effective January 1, 2023. As part of a planned transition, Mark Schiller will continue to serve as President and CEO until December 31, 2022, at which point, he will become a non-executive director on the Board and will serve as an ongoing resource to Ms. Davidson. Ms. Davidson has also been appointed as a member of the Company's Board of Directors, effective January 1, 2023, increasing the size of the Board of Directors to nine directors. She most recently served as President of the Americas for Glanbia Performance Nutrition.

08:34 EST Navidea enrolls 50th participant in Phase 3 trial in Rheumatoid Arthritis - Navidea Biopharmaceuticals announced enrollment of the 50th participant in the Company's pivotal NAV3-33 Phase 3 clinical trial titled "Evaluation of Tc 99m Tilmanocept Imaging for the Early Prediction of Anti-TNFa Therapy Response in Patients with Moderate to Severe Active Rheumatoid Arthritis" This Phase 3 trial will establish the ability of Tc99m tilmanocept imaging to serve as an early predictor of treatment response in rheumatoid arthritis patients switching to an anti-TNFa therapy, addressing a large unmet medical need. Overall trial size will range from 198-672 patients, with enrollment targeted to achieve a minimum of 100 clinical responders to anti-TNFa therapy and 98 non-responders. Rheumatoid arthritis is a serious and potentially debilitating disease. The standard practice of treating RA is to monitor patients starting new RA therapies over a course of three to six months and, in those patients for which the new therapies prove to be ineffective, to change their treatments to an alternative therapy. This trial-and-error process of appropriate treatment selection may take several months to more than a year to arrive at an adequate treatment for any RA patient. Imaging with Tc99m tilmanocept, a synthetic molecule with high affinity to CD206 receptors expressed on activated macrophages, offers the potential to provide an early predictor of clinical response by providing an objective, quantifiable readout of changes in macrophage density in the joints of patients undergoing initiation or change of therapy. These macrophage density changes may be observable weeks before disease modification can be detected with standard clinical assessments. Additionally, in patients with a low-macrophage type of RA who have been shown to be less responsive to anti-TNFa therapy, an initial baseline scan alone could point their physicians to another therapy type that has a better chance of success than an anti-TNFa.

08:33 EST iCAD, Google Health enter development, commercialization agreement - iCAD (ICAD) announced a strategic development and commercialization agreement with Google Health (GOOG, GOOGL) to integrate its artificial intelligence technology into iCAD's portfolio of breast imaging AI solutions. Marking the first commercial partnership Google Health has entered into to introduce its breast imaging AI into clinical practice, the companies will work together to enhance iCAD's market-leading breast cancer AI solutions for mammography and expand access to the technology to millions of women and providers worldwide. iCAD will also leverage Google Cloud's secure, scalable infrastructure, accelerating the time to market for iCAD's cloud-hosted offerings. Under the definitive agreement, Google has licensed its AI technology for breast cancer and personalized risk assessment to iCAD. iCAD will apply the licensed technology to further improve its 3D and 2D AI algorithms and will commercialize developed products.

08:32 EST Selecta Biosciences appoints Blaine Davis as CFO - Selecta Biosciences (SELB) announced the appointment of Blaine Davis as CFO, effective today, November 28, 2022. Prior to joining Selecta, Mr. Davis served as CFO of Protara Therapeutics (TARA), where he built the finance function from the ground up across all financial verticals.

08:29 EST Lantheus announces China NMPA approval of DEFINITY - Lantheus Holdings announced that the Center for Drug Evaluation of China's National Medical Products Administration has approved the Import Drug License for Perflutren Lipid Microsphere Injectable Suspension the Company's diagnostic ultrasound enhancing agent for patients with suboptimal echocardiograms. The Company's partner, China Resources Double-Crane Pharmaceutical, will be responsible for commercializing DEFINITY in China under a local brand name. Under the distribution agreement, Lantheus will supply DEFINITY to CR Double-Crane for a launch in China. With this approval, DEFINITY is indicated in China for use in patients with suboptimal conventional echocardiography and to better identify the left ventricular endocardial border. Lantheus entered into a development and distribution arrangement with CR Double-Crane for the commercialization of DEFINITY in China, Hong Kong and Macau. As part of the agreement with Lantheus, CR Double-Crane conducted confirmatory clinical trials with DEFINITY on Lantheus' behalf in pursuit of cardiac, liver and kidney imaging indications, as well as a pharmacokinetic study.

08:27 EST Clene announces presentation of VISIONARY-MS trial results at PACTRIMS - Clene announced that the VISIONARY-MS trial results were featured as a platform presentation by Professor Michael Barnett, MBBS FRACP PhD at the 14th Annual Singapore Pan-Asian Committee on Treatment and Research in Multiple Sclerosis Congress held November 24-26. The platform presentation titled, "VISIONARY-MS Top-line Results: A Phase 2, Randomized, Double-Blind, Parallel Group, Placebo-Controlled Study to Assess the Safety and Efficacy of CNM-Au8, a Catalytically Active Gold Nanocrystal Suspension in Relapsing Multiple Sclerosis," provided proof-of-concept evidence for global neurological improvement as assessed by the modified Multiple Sclerosis Functional Composite, evaluating low contrast vision, cognition, upper extremity function, and walking speed with CNM-Au8 as adjunct to approved background immunomodulatory disease modifying therapies in stable MS patients. VISIONARY-MS investigated the efficacy and safety of CNM-Au8 versus placebo over 48 weeks in stable relapsing remitting MS participants with chronic optic neuropathy. Nearly all participants were treated with highly effective DMTs as background standard of care. The primary endpoint, evaluating change in low contrast letter acuity compared to placebo at week 48, demonstrated significant improvement. Secondary endpoint of global neurological improvement, the modified Multiple Sclerosis Functional Composite, mean standardized change compared to placebo at week 48, demonstrated significant improvement. Consistent improvements favoring CNM-Au8 were observed across paraclinical biomarkers, including multifocal visual evoked potential amplitude and latency, measurements of retinal structure with optical coherence tomography, and novel MRI endpoints examining myelin and axonal integrity. These data provided consistent supportive evidence from neurophysiology, retinal imaging, and novel MRI markers for the potential neuroprotective and remyelinating effects of CNM-Au8 treatment. Placebo treated patients generally worsened across clinical and paraclinical measures during the 48-week period. CNM-Au8 was well-tolerated, and no significant safety findings were observed. As announced in February 2022, the VISIONARY-MS trial was stopped prematurely due to COVID-19 pandemic operational challenges, enrolling 73 out of the 150 planned participants. Due to limited enrollment, the threshold for significance was pre-specified at p=0.10 prior to database lock and submitted to the FDA in the statistical analysis plan. The primary analysis was conducted in the modified intent to treat population, which censored invalid data, including data from a single site with LCLA testing execution errors, and the timed 25-foot walk data from one subject at another site with a change in mobility assist device. The ITT results incorporating the invalid data were not significant, though directionally consistent with the mITT results.

08:24 EST Cidara Therapeutics, Melinta announce publication on ReSTORE trial of rezafungin - Cidara Therapeutics announced the peer-reviewed publication of data from the completed pivotal ReSTORE Phase 3 clinical trial evaluating the efficacy and safety of its once-weekly antifungal candidate rezafungin as a potential treatment for candidemia and invasive candidiasis. The data, published in The Lancet titled, "Rezafungin versus caspofungin for treatment of candidaemia and invasive candidiasis: a multicentre, double-blind, double-dummy, randomised phase 3 trial," demonstrate the statistical noninferiority of rezafungin dosed once-weekly, versus the current standard of care caspofungin, dosed once-daily. Melinta announced earlier this year that it had acquired the exclusive rights to commercialize rezafungin in the U.S. from Cidara. Cidara reported positive topline results from ReSTORE in December 2021. Rezafungin met the primary endpoint for the U.S. Food and Drug Administration New Drug Application submission of all-cause mortality at Day 30, and also met the primary endpoint for the European Medicines Agency Marketing Authorization Application submission of global cure at Day 14. In the study, researchers evaluated one 400 milligram dose of rezafungin for the first week followed by 200 mg of rezafungin dosed once-weekly for up to four weeks in total. Rezafungin was generally well tolerated and had a similar safety profile to caspofungin. The FDA has accepted for filing and granted Priority Review to Cidara's NDA for rezafungin for the treatment of candidemia and invasive candidiasis. The FDA has assigned a Prescription Drug User Fee Act target action date of March 22, 2023, enabled by rezafungin's designation as a Qualified Infectious Disease Product and has indicated that the application will be discussed during a scheduled meeting of the Antimicrobial Drugs Advisory Committee on January 24, 2023. Cidara retains the rights to rezafungin in Japan and in addition to licensing the commercial rights to Melinta in the U.S., has licensed the commercial rights in all other geographies to Mundipharma.

08:20 EST ContraFect announces ANSM approval of CTA for exebacase - ContraFect Corporation announces that ANSM, the French National Agency for the Safety of Medicines and Health Products, has authorized its Clinical Trial Application for the study of intra-articularly administered exebacase, in the setting of a minimally-invasive arthroscopic debridement, antibiotics, irrigation, and retention procedure in patients with chronic prosthetic joint infection of the knee due to Staphylococcus aureus or Coagulase-Negative Staphylococci. The Phase 1b/2 study of exebacase is a randomized, double-blind, placebo-controlled two-part clinical study to be conducted in France to assess the efficacy and safety of exebacase in the setting of an arthroscopic DAIR procedure in patients with chronic PJI of the knee due to S. aureus and/or CoNS. Part 1 will evaluate the safety, PK, clinical outcomes, and microbiologic response in patients through Day 42. Up to 2 dose levels of intra-articularly administered exebacase in addition to systemic antibiotics will be studied in up to 2 patient cohorts. Part 2 will consist of a long-term follow-up study of safety and efficacy parameters in patients who complete Part 1 of the study. Follow-up assessments will be performed on Days 90, 180, 360 and 720.

08:18 EST Grom Social's Curiosity Ink Media announces Santa.com exclusive product drop - Grom Social Enterprises' Curiosity Ink Media is celebrating Cyber Monday by offering the first 250 shoppers who purchase $150 or more in the site's e-commerce marketplace will receive a limited-edition, handcrafted glass Santa Claus ornament valued at $59.99.

08:17 EST Crinetics says CRN04777 study not yet permitted to proceed - Crinetics Pharmaceuticals provided an update on its development program for CRN04777, an investigational, oral somatostatin receptor type 5 agonist being developed as a treatment for congenital hyperinsulinism. On October 24, 2022, Crinetics submitted an Investigational New Drug application to the United States Food and Drug Administration to initiate the first U.S. clinical study of CRN04777, which is designed to evaluate the compound in a pediatric population. On November 22, 2022, the FDA informed the company via telephonic communication that the proposed Phase 2 clinical study was not yet permitted to proceed. The FDA indicated that it would provide the company with the basis for its decision within 30 days. Crinetics plans to engage with the FDA to understand the additional information or clarifications that may be required before the FDA will allow the study to proceed. CRN04777 was previously evaluated in 78 adult healthy volunteers in a Phase 1 single- and multiple-ascending dose clinical trial under a Clinical Trial Application in Germany. Results from these studies showed CRN04777 was well tolerated at doses from 30 mg to 120 mg. No serious adverse events were reported and no discontinuations due to adverse events occurred. All adverse events were considered to be mild to moderate.

08:14 EST Jazz to present six presentations on advancements in epilepsy outcomes - Jazz Pharmaceuticals announced that six company-sponsored Epidiolex oral solution presentations, including three late-breaking abstracts, will be shared at the upcoming 2022 American Epilepsy Society, AES, annual meeting, which will be held December 2-6, 2022, in Nashville, TN. "We understand the significant, lifelong implications of severe, childhood-onset epilepsy on both patients and their families. We continually strive to improve patient outcomes and are proud to present data that includes caregiver-reported insight into Epidiolex's effects on seizure and non-seizure outcomes in both children and adults living with Lennox-Gastaut Syndrome and Dravet Syndrome," said Kelvin Tan, MB BCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals. "In addition, we are sharing long-term Phase 3 trial findings which demonstrate Epidiolex's ability to reduce tuberous sclerosis complex-related seizures over the course of three years of treatment - further underscoring that Epidiolex is an important treatment option in an area with significant unmet patient need." Presentation highlights include: Two Late Breaker Abstracts Featuring Subgroup Analysis of BECOME Caregiver Survey Results: The BECOME survey is a global outcomes survey of caregivers of patients with LGS or DS that characterized and quantified the seizure and non-seizure outcomes of Epidiolex treatment. The results demonstrate that a substantial proportion of the caregivers of people with LGS or DS treated with Epidiolex reported improvements in many patients' seizure and non-seizure outcomes, regardless of age group. Long-term Safety and Efficacy of Add-on Cannabidiol for Seizures Associated with Tuberous Sclerosis Complex: 3-Year Results From GWPCARE6 Open-Label Extension: Findings suggest that long-term, add-on Epidiolex treatment was well tolerated and demonstrated sustained reductions in TSC-associated seizures in patients for up to 156 weeks. REST LGS TOOL: The Refractory Epilepsy Screening Tool for LGS patients was designed to improve identification and treatment of patients with LGS. Using REST-LGS, this study identified that over half of the individuals without a previous LGS diagnosis should be referred for further diagnostic evaluation at a specialized epilepsy center, and further validated the REST-LGS for the identification of potential LGS patients with DRE and IDD.

08:11 EST Praxis to advance PRAX-562 Phase 2 study in pediatric patients - Praxis Precision Medicines announced plans to initiate the PRAX-562 Phase 2 EMBOLD study for the treatment of pediatric patients with developmental and epileptic encephalopathies, following U.S. Food and Drug Administration authorization to proceed with the study as proposed by Praxis, up to the planned maximum dose of 1.0 mg/kg/day. The EMBOLD Study is expected to initiate in the U.S in the first quarter of 2023, with two distinct cohorts in early-onset SCN2A-DEE and SCN8A-DEE patients. Topline results for both cohorts are expected in the second half of 2023. The EMBOLD Study is a randomized, double-blind, placebo-controlled Phase 2 clinical trial to evaluate the safety, tolerability, efficacy and pharmacokinetics of PRAX-562 in pediatric participants aged 2 to 18 years with DEEs, followed by an open-label extension. Approximately 20 participants will be enrolled in a total of 2 distinct cohorts.

08:10 EST Lineage Cell announces Genentech launch of OpRegen study for GA - Lineage Cell Therapeutics (LCTX) announced that its partner Genentech, a member of the Roche Group (RHHBY), has launched a Phase 2a, multicenter, open-label, single arm clinical study of RG6501 a retinal pigment epithelial cell therapy. The study is intended to optimize subretinal surgical delivery and evaluate the safety and activity of OpRegen in approximately 30, and up to 60 patients with geographic atrophy GA secondary to age-related macular degeneration. The primary objectives of the study are to evaluate (i) the proportion of patients with subretinal surgical delivery of OpRegen to target regions under the retina, and (ii) to evaluate the safety of subretinal surgical delivery of OpRegen as measured by the incidence and severity of procedure-related adverse events at 3 months following surgery. A key secondary objective is to evaluate the proportion of patients with qualitative improvement in retinal structure, as determined by Optical Coherence Tomography imaging, within 3 months following surgery. RG6501, OpRegen, is currently being developed under an exclusive worldwide collaboration between Lineage, Roche and Genentech. "We are excited for the launch of this Phase 2a study, where one of the key objectives is to optimize the delivery of OpRegen to achieve the best outcomes," stated Seppi Lin, Vice President of OMNI Early Clinical Development at Genentech. "This study will provide key insights for the future development of the OpRegen program. Geographic Atrophy, GA , secondary to AMD is a disease area of high unmet need with no approved therapies, and we are committed to developing effective and innovative medicines for patients with serious eye diseases."

08:08 EST Patrick Industries completes acquisition of Transhield - Patrick Industries announced that it has completed the acquisition of Transhield, a premier designer and manufacturer of customized and proprietary protection solutions for the marine, military and industrial markets. "We are extremely excited to partner with Jim Glick, Matt Peat and the entire Transhield team," said Andy Nemeth, Chief Executive Officer of Patrick. "Transhield's innovative and quality product solutions have significant potential across multiple market sectors, and their culture, spirit, and industry reputation for customer service are an ideal fit within our portfolio of companies and independent brands. As with previous acquisitions, we will provide a financial and operational foundation that will allow Transhield to continue to drive its strategic vision and capitalize on its core competencies." The acquisition is expected to be immediately accretive to net income per share. The business will continue to operate on a stand-alone basis under the Transhield name in its existing facilities.

08:07 EST ViaSat-3 satellite completes final integrated satellite test - ViaSat announced the ViaSat-3 Americas satellite has completed its Final Integrated Satellite Test, FIST, and has now progressed to the Flight Final phase of integration where it is undergoing final build-up to its flight configuration. FIST is designed to test all the satellite's payload and bus systems to confirm they function properly following the stresses of mechanical environmental testing, which simulated the launch of the spacecraft. The satellite had already successfully completed mechanical environmental testing and thermal vacuum testing that simulated vacuum and extreme hot and cold conditions of space where the satellite will operate during its expected 15-year lifetime. "With the completion of the Final Integrated Satellite Test, we now have final confirmation that the satellite design and build process has produced a spacecraft that is ready for launch. We can now progress to the final buildup for flight and look forward to finishing the satellite soon and preparing it for transport from Boeing's facility in El Segundo, California to Cape Canaveral, Florida," said Dave Ryan, president of Space & Commercial Networks at Viasat.

08:06 EST Agnico Eagle publishes first climate action report - Agnico Eagle Mines reports that it has released its first Climate Action Report, aligned with the Task Force on Climate-related Financial Disclosures recommendations. The Company is committed to be Net-Zero by 2050 in absolute Scope 1 and Scope 2 carbon emissions and, to this end, it has set an interim carbon reduction target of 30% of 2021 Scope 1 and Scope 2 greenhouse gas emissions by 2030. "The risks associated with a changing climate have never been clearer and we understand the importance of managing these risks to build a better business, capitalize on future opportunities and communicate effectively with our stakeholders," said Agnico Eagle's President and CEO Ammar Al-Joundi. "We hold ourselves accountable to high ESG standards and have strategies in place to adapt to and mitigate the impacts of climate change," added Al-Joundi.

08:05 EST CareTrust REIT appoints James Callister Chief Investment Officer - The Board of Directors of CareTrust REIT announced the appointment of James Callister as Chief Investment Officer, to be effective as of December 31. Mr. Callister will succeed Mark Lamb, who will be leaving the company after a transition period to pursue entrepreneurial opportunities. Mr. Callister currently serves as CareTrust's Executive Vice President.

08:03 EST Braskem joins MIT Energy Initiative to advance energy transition - Braskem joined the MIT Energy Initiative to help support and fund relevant research to advance the energy transition. MITEI serves as MIT's hub for energy research, education, and outreach. In October 2021, the initiative launched the Future Energy Systems Center, a new research consortium designed to address the climate crisis and examine the role energy systems have in addressing it. "We are honored to join the MIT Energy Initiative alongside several leaders within the industrials space that share our dedication to creating a safer planet and a more sustainable future," said Joshua Taylor, Open Innovation Specialist at Braskem America. "Through this membership, we hope to gain insights that will support Braskem's sustainability journey as well as contribute to research that is critical to addressing the climate crisis and creating solutions to reimagine the world's energy systems."

07:44 EST Zynerba announces publication of data from Phase 3 CONNECT-FX study - Zynerba Pharmaceuticals announced that the results from the Phase 3 CONNECT-FX study of Zygel for the treatment of behavioral symptoms in children and adolescents with Fragile X syndrome were published in the Journal of Neurodevelopmental Disorders. The paper titled, "A Randomized, Controlled Trial of ZYN002 Cannabidiol Transdermal Gel in Children and Adolescents with Fragile X Syndrome," details how Zygel was well tolerated in patients with FXS and demonstrated efficacy with a favorable benefit risk profile in patients with greater than or equal to90% methylation of the FMR1 gene, in whom gene silencing is most likely, and the impact of FXS is typically most severe. CONNECT-FX was a randomized, double-blind, multinational, 14-week study to evaluate the efficacy and safety of Zygel in children and adolescents aged 3 to 17 years. A total of 212 patients were randomized to 12 weeks of Zygel or placebo, as add-on to standard of care. The trial was conducted at 21 investigational centers in the U.S., Australia and New Zealand. The primary endpoint assessed change in social avoidance measured by the Aberrant Behavior Checklist-Community Edition FXS SA subscale in the full cohort of patients with full mutation FXS, regardless of the FMR1 gene methylation status. Ad hoc analyses assessed efficacy in patients with greater than or equal to90% and 100% methylation of the promoter region of the FMR1 gene, in whom FMR1 gene silencing is most likely. Although statistical significance for the primary endpoint was not achieved in the full cohort, significant improvement was demonstrated in patients with greater than or equal to90% methylation of FMR1, representing 80% of the overall study population. This group also achieved statistically significant improvements in Caregiver Global Impression-Change in SA and Isolation, Irritable and Disruptive Behaviors, and Social Interactions. Similar results were seen in patients with 100% methylation of FMR1, representing 65% of the study population. Zygel was generally well tolerated. All treatment-emergent adverse events were mild or moderate. The most common treatment-related TEAE was application site pain.

07:39 EST Bluevec selects Draganfly to create joint solutions for UAS threat detection - Draganfly announces that Bluvec has selected Draganfly to create joint solutions enabling specific Military and Civil UAS Threat Detection Intervention. Draganfly and Bluvec will collaborate to develop joint solutions for counter-drone technology to improve threat detection management and intervention, particularly at crucial infrastructures such as airports, energy facilities, and civil air defense. Bluvec's counter-UAS platform will be integrated with Draganfly's Commander 3XL UAV to create a unique, innovative solution that will extend the range of Bluvec's existing products and introduce additional capabilities such as remote situational reconnaissance, patrol and intervention. The Commander 3 XL is an easy-to-deploy, modular multirotor UAV with the ability to carry up to 10 kg as part of its interchangeable payload system. Draganfly, in addition, will also be a distributor of Bluvec solutions and will act as a collaborator to help grow the global adoption of critical counter-UAV infrastructure.

07:37 EST Rio2 Limited provides Fenix Gold, corporate update - Rio2 is providing an update of its activities and a corporate update following the decision to file an administrative appeal before the Ministries Committee on August 31, 2022, to appeal the Atacama Regional Evaluation Commission's decision not to approve the Environmental Impact Assessment for its Fenix Gold Project in Chile. Chilean voters resoundingly rejected a new, progressive constitution in a referendum held on Sunday, September 4, 2022, following a nearly two-year process that aimed to reflect a broad array of voices in the nation's proposed new constitution. With the ballots counted, 62% of voters rejected the proposal with 38% voting in favor, according to the Chile Electoral Service. The proposed constitution was rejected in all of Chile's provinces, with 60% of voters rejecting the proposal and 40% voting in favor in the Atacama Region, where the Fenix Gold Project is located. As a result of the vote, all political parties have vowed to work with the current government to develop a new constitution that better reflects the wishes of the Chilean people. There is currently no publicly announced timeframe for the preparation of a new constitution. On September 6, 2022, less than six months into his Presidency, President Boric announced a major overhaul of his cabinet after voters overwhelmingly rejected the proposed new constitution that was key to his government's agenda. President Boric announced replacements to his ministers of mining, energy and the interior. He also replaced the minister secretary-general, who oversees the President's legislative agenda. On September 12, 2022, InvestChile reported that Chile's government presented the "Let's Invest in Chile" plan, a package of measures that aims to increase investment by five percentage points in 2023. The plan, which came into effect in September 2022, consists of 28 measures divided into six areas of action: providing tax incentives for private investment; improving access to financing; improving public investment; promoting foreign investment; enhancing the effectiveness of regulation and permit procedures; and promoting public/private partnerships for investment. Of the 28 measures being implemented, the following 6 measures are pertinent to Rio2 and its Fenix Gold Project. InvestChile investment attache offices will be reopened abroad. Investment attache offices will reopen in Europe and North America during the fourth quarter of 2022. These markets account for 60% of foreign direct investment stock in Chile. This measure is expected to result in the materialization of projects worth more than US$1.5 billion in 2023. Strengthening of the InvestChile investment promotion team. The institutional structure and main functions of the agency will be ready during September 2022. This initiative is expected to significantly increase the number of investment projects and facilitate projects that are already under evaluation, attracting additional investment of more than US$2 billion in 2023. Funding for strengthening critical services in the processing of projects. A special fund will be created in the 2023 budget to speed up the processing of the permits required for undertaking investments. A coordinating agency will be created to implement a single point of contact for sectorial permits from 2023. A committee of experts will be entrusted with the design of a new institutional framework that effectively coordinates the granting of sectoral permits by the State. Public/private initiatives for promoting investment. Four public/private working groups will be convened in sectors such as construction, energy, transport and mining to create a set of measures that will reduce the number of stalled construction projects and create more favorable conditions for upcoming projects. Formation of a regional public investment operating committee under the coordination of the Economy Ministry. A permanent working group will be set up between the Energy, Mining and Economy Ministries, InvestChile and the development and investment divisions of each regional government to periodically monitor the progress of projects in each region. Fenix Gold is working closely with InvestChile to maximize its participation and exposure to the Chilean government's new investment plan. Since early September, the Fenix Gold team has been extremely proactive in coordinating meetings with government ministries and government authorities both regionally and nationally to present our case in preparation for the appeals process. To date, Fenix Gold has not been advised of exact timing for when the Committee of Ministers will review the Company's appeal.

07:35 EST New Pacific Metals reports updates MRE for Silver Sand deposit, Bolivia - New Pacific Metals announces an updated Mineral Resource Estimate, MRE, for the Silver Sand Project, which is part of the on-going Preliminary Economic Assessment, PEA, study of the Project. The PEA study is on track to be completed by the end of 2022. The Mineral Resource is reported in accordance with National Instrument 43-101 for its 100% owned Silver Sand Project, Bolivia. The estimate was completed by AMC Mining Consultants.

07:33 EST CinCor Pharma announces Phase 2 HALO trial does not meet primary endpoint - CinCor Pharma announced the topline results and completion of its Phase 2 HALO trial evaluating the efficacy and safety of baxdrostat in patients with uncontrolled hypertension taking up to two blood pressure medications at the maximally tolerated doses. Baxdrostat is a once daily potentially first-in-class, highly selective aldosterone synthase inhibitor. While HALO did not achieve statistical significance on its primary endpoint evaluating change from baseline in mean seated systolic blood pressure in the intention to treat population, a pre-specified subgroup analysis of non-Hispanic patients representing approximately 81-89% of the hypertension population in the United States, demonstrated a placebo-adjusted reduction in SBP of 12.6 mmHg at the 2 mg dose. The safety profile and tolerability of baxdrostat was consistent with previously reported Phase 2 BrigHtn data in resistant hypertension. HALO informs target populations for planned Phase 3 trials: HALO did not achieve its primary endpoint of statistically significant change from baseline in mean seated SBP versus placebo in the ITT population; however, statistically significant reduction in SBP in the prespecified non-Hispanic subgroup analysis was demonstrated; Hispanic or Latino patients represented 53% of the ITT population of the study; The non-Hispanic population of HALO represented 46% of the ITT population in the study but represents approximately 81-89% of the hypertensive population of the U.S. Safety and tolerability findings reinforce a consistent, and well-tolerated profile: No drug related serious adverse events observed and no major safety concerns were reported across all three dose cohorts tested after 8 weeks of treatment; No patient discontinued the study due to treatment-related adverse events; Baxdrostat demonstrated a favorable safety and tolerability profile with 3 cases of moderate hyperkalemia after 8 weeks of treatment none of which led to study discontinuation; Treatment-emergent serious adverse events were reported in 2 patients after 8 weeks of treatment; no SAE was deemed related to baxdrostat; 85% of patients that completed HALO enrolled in the ongoing open label extension trial evaluating the safety and efficacy of baxdrostat over 52 weeks. The HALO trial was a Phase 2 randomized, double-blind, placebo-controlled, multicenter, parallel-group, clinical trial designed to assess the safety and efficacy of baxdrostat in subjects taking up to two antihypertensive agents at their maximally tolerated dosages. The trial evaluated three active doses of baxdrostat compared to placebo control in 249 patients randomized across all four dosing cohorts, with 249 patients completing. The primary endpoint of the trial was the change in SBP after eight weeks of treatment. Background antihypertensive therapy was to be discontinued after these eight weeks, and patients only took baxdrostat at the 2.0 mg dose for four additional weeks in Part 2 of the trial to characterize monotherapy responses and to enable long-term safety assessments of the drug in the ongoing 52-week open label extension study that follows the HALO trial, which is expected to be completed in the second half of 2023.

07:32 EST Camping World to acquire RV Solutions, terms undisclosed - Camping World announced an agreement to acquire RV Solutions. This transaction includes two RV Dealership locations, RV Solutions and Airstream of San Diego along with one standalone parts and service center in El Cajon, California. The acquisition of these facilities is slated to be finalized in first quarter 2023.

07:17 EST Signal Gold acquires exploration licenses adjacent to Goldboro Mineral Resource - Signal Gold acquired a 100% interest in six exploration licenses adjacent to the Goldboro Mineral Resource at its Goldboro Gold Project in Nova Scotia, Canada. As a result, Signal Gold has increased its exploration license area from 599 hectares to 3,756 hectares. This represents a significant milestone in the development of the Project as these exploration licenses cover the surface area which will be required for much of the Project's key infrastructure. It also adds further exploration opportunity along strike of the Goldboro Mineral Resource, as the additional licenses include the strike continuity of the host structure of the Goldboro Deposit, bringing the total known and prospective strike length to 7.5 kilometres. The Company acquired the exploration licenses from Meguma Gold Inc. for a total purchase price of $700,000, comprised of $400,000 in cash and $300,000 in common shares of Signal Gold at a deemed value of $0.333 per common share, based on the 20-day volume weighted average price as of November 16, 2022, resulting in the issuance of 900,901 common shares of the Company. The Company also granted to Meguma Gold Inc. a 1.0% royalty over the licenses acquired, capped at $1,000,000 of total payments, and assumed an existing 2% gross royalty which applies to five of the exploration licenses acquired.

07:15 EST BioCryst announces Israeli MOH approval of ORLADEYO - BioCryst Pharmaceuticals announced that the Israeli Ministry of Health has granted marketing authorization for oral, once-daily ORLADEYO to prevent attacks of hereditary angioedema in adults and pediatric patients 12 years of age and older in Israel.

07:12 EST Asante Gold completes final payment for Bibiani Gold Mine - Asante Gold Corporation (ASGOF) announced that the Company has completed the final payment to Resolute Mining Limited (RMGGF) pursuant to an amendment letter agreement that was signed on August 24, 2022. The amendment provided for a 90-day extension of time for the final tranche deferred payment of $30M in connection with the $90M acquisition of Mensin Gold Bibiani Limited, which subsidiary company owns a 90% interest in the Bibiani Gold Mine. The revised payment terms included payment of $10M on or before September 19, 2022, $10M on or before October 19, 2022 and the final payment due on or before November 18, 2022. Bibiani Gold Mine - Timeline from Acquisition to Production: Asante has successfully advanced development of the Bibiani Gold Mine from initial acquisition to commercial production over the past 15 months: Acquired the Bibiani Gold Mine from Resolute on August 4, 2021; Initiated refurbishment of the process plant September 5, 2021; Commenced open pit mining operations February 28, 2022; Completed refurbishment and commissioning of the process plant, with start of operations June 2, 2022; First gold pour completed July 7, 2022, two months ahead of schedule; Filed an updated NI 43-101 report for the Bibiani Gold Mine on September 1, 2022; Commercial production announced November 10, 2022; Final payment for Bibiani Gold Mine completed November 28, 2022; Near mine exploration programs, with planned drilling of approximately 30,000 metres per year for 2022, 2023 and 2024, are expected to extend the Bibiani open pit Life of Mine of 8.3 years. With respect to the recent announcement by the Government of Ghana requiring gold producers to sell 20% of annual production in Cedis, the Company notes that the initiative has been discussed with gold producers in Ghana, represented by the Chamber of Mines for several months. The Company notes that the local currency expenditure requirement of Asante and most mining companies far exceeds this request. The feedback presented by the Chamber of Mines has been that the industry in Ghana exceeds this level of expenditure in Cedis. The Company confirms that this requirement will not affect its activities and conduct of business.

07:10 EST Momentus contracts with Australian research centrer to place satellite in orbit - Momentus has signed a contract with the CUAVA Training Centre at the University of Sydney to deploy the CUAVA-2 CubeSat in low-Earth orbit in October 2023. CUAVA is the Australian Research Council Training Centre for CubeSats, Uncrewed Aerial Vehicles, and their Applications. CUAVA is a partnership centered at the University of Sydney that aims to fundamentally change the capabilities and applications of CubeSats to create major commercial value with wide applications. "Momentus is proud to partner with CUAVA, a leading Australian research center," said Momentus Chief Executive Officer John Rood. "Innovation and pushing the boundaries of technology is what we love to do at Momentus. We look forward to supporting CUAVA's mission to use leading edge capabilities in space to improve life on Earth."

07:07 EST Xortx completes screening, enrollment in Bridging Pharmacokinetics Study - XORTX Therapeutics announced the screening and enrollment of the last remaining subjects into the XRX-OXY-101 Bridging Pharmacokinetics Study, including initiation of dosing of all subjects enrolled in Part 4 of the Study. The Study has been designed to characterize the improved bioavailability of various formulations, to assess the impact of dose on exposure, as well as the safety and pharmacokinetic properties of multiple doses of the Company's proprietary formulation of oxypurinol.

07:04 EST Singularity Future Technology receives positive Nasdaq listing determination - Singularity Future Technology announced that by a decision dated November 22, 2022, a Nasdaq Hearings Panel granted Singularity's request for continued listing on The Nasdaq Stock Market, subject to the Company evidencing compliance with Nasdaq's filing requirement on or before February 28, 2023, and certain other conditions. The Company is working to file its delinquent periodic reports with the Securities and Exchange Commission as soon as practicable and thereby timely evidence compliance with the terms of the Panel's decision. However, there can be no assurances that the Company will be able to do so.

07:02 EST Builders FirstSource board authorizes $1B increase to stock repurchase plan - Builders FirstSource announced that its Board of Directors approved an increase to the Company's existing stock repurchase plan in the amount of $1 billion, for a total of approximately $1.5 billion inclusive of the remaining outstanding authorization at the end of the third quarter of 2022. As previously reported on November 8, 2022, under the share repurchase programs authorized by the Board of Directors since August of 2021, the Company repurchased a total of 61.0 million shares of common stock, or approximately 29.5% of the Company's total shares outstanding, at an average price of $62.23 per share for an aggregate investment of $3.8 billion. Since that time, the Company has repurchased an additional approximately 1.1 million shares for $68 million at an average price of $63.05 per share.

06:59 EST Aimco expands commitment to governance enhancements - Apartment Investment and Management Company expanded on its commitment to enhance corporate governance, announcing that its Board has committed to the following actions: Opt Out of MUTA: The Aimco Board will, prior to the 2023 annual meeting, opt out of the provisions of the Maryland Unsolicited Takeover Act, or MUTA, including those that would otherwise allow it to re-classify the Board without the approval of stockholders. Declassify the Board in 2023: The Aimco Board will opt out of MUTA prior to the 2023 annual meeting and take any and all other actions necessary to ensure that all Aimco directors stand for election to annual terms at the 2023 annual meeting. Transition Timing of the Annual Meeting Date: The Board will move the date of the Company's annual meeting so the 2024 annual meeting will be held by the end of the second quarter of 2024. The Board intends to hold the 2023 annual meeting by the end of the third quarter of 2023. Ask Aimco's stockholders to Approve Certain Charter Amendments to Eliminate Super-Majority Requirements and Expand Stockholder Rights to Replace Directors: The Board will ask Aimco's stockholders to, and will recommend that they, approve amendments to Aimco's charter at the 2023 annual meeting. Once approved by stockholders this will: Lower the threshold required for stockholders to amend all portions of Aimco's Bylaws to a simple majority of shares outstanding; and Lower the threshold for stockholders to remove directors to a simple majority of shares outstanding, eliminate the requirement that such removal be for "cause", and allow shareholders to appoint directors to fill vacancies arising out of removals by stockholders. Amend Aimco's Bylaws to Lower Threshold for Stockholders to Call a Special Meeting to 15%: The Board will, effective as of the 2023 annual meeting, amend Aimco's Bylaws to lower the threshold for stockholders to call a special meeting to 15% of shares outstanding, and also allow stockholders to amend the Bylaws to set the size or range of the size of the Board .

06:54 EST US Foods appoints Dave Flitman as CEO - US Foods Holding (USFD) announced that Dave Flitman will become CEO effective Jan. 5, 2023. Flitman will also be a member of the US Foods Board of Directors. Since April 2021, Flitman has served as President and CEO of Builders FirstSource (BLDR). With a permanent CEO in place, Bob Dutkowsky will become non-executive Chairman of the US Foods Board of Directors effective Jan. 5, 2023. Andrew Iacobucci, Interim CEO, will continue to lead US Foods until Flitman joins the company.

06:49 EST National Energy Services secures directional drilling services contract - National Energy Services Reunited has announced that the company has been awarded a long term contract for Directional Drilling services in Kuwait, covering Directional Drilling, Measurements while Drilling, Performance Drilling, Well Engineering and Logging While Drilling services for five years, with an option to extend an additional year.

06:46 EST New Found Gold announces results from diamond drill hole - New Found Gold announced the results from one diamond drill hole that was completed as part of a program designed to follow up on newly discovered high-grade gold at Keats West located west of the highly prospective Appleton Fault Zone. New Found's 100%-owned Queensway project comprises a 1,650km2 area, accessible via the Trans-Canada Highway, 15km west of Gander, Newfoundland and Labrador. Follow-up drilling targeting the new Keats West discovery area intersected 42.6 g/t Au over 32m in NFGC-22-960 that contains a higher-grade interval of 171.6 g/t Au over 6.5m and is situated at a vertical depth of 125m. This intercept is located 200m down-plunge of previously reported 18.6 g/t Au over 15.95m in NFGC-22-773 and 25m along strike of previously reported intercept of 17.9 g/t Au over 4.2m in NFGC-22-681. These holes are all interpreted to occur within the same host structures. NFGC-22-960 also intersected a domain of near-surface, lower-grade gold mineralization over a cumulative width of 19.8m, within an interval of 29.8m, and demonstrating grades ranging from 1.18 to 2.14 g/t Au. Broad domains of lower-grade gold have now been intercepted in multiple holes over a footprint spanning 280m x 130m at Keats West. Keats West is open along strike and down-dip. Exploration drilling is ongoing with two drills working to expand on this new discovery. Greg Matheson, COO for New Found stated: "Keats West is turning into a zone of special interest for New Found. Following today's release, we have now seen gold grades from low through to high, both over impressive widths, indicating the presence of a strong gold mineralizing system. What makes this 32m intercept notable is the number of significant assay intervals that are present throughout it. Nineteen assay intervals exceeded 10 g/t Au as shown in Table 3. This interval is comprised of a substantial damage zone containing a high-density of epizonal-style quartz veining throughout including a massive vein segment spanning a down-hole length of 6m."

06:42 EST NWTN Inc. says UAE electric vehicle assembly facility to be complete in Q4 - NWTN Inc. announced that construction on its UAE electric vehicle assembly facility in Khalifa Industrial Zone Abu Dhabi is on schedule and will be completed in Q4 of 2022. NWTN signed a lease agreement with KEZAD Group for the facility, which measures approximately 270,000 square feet, in September of 2022 to establish NWTN's first EV assembly facility in Abu Dhabi. The facility will serve the growing demand for sustainable transport options in the Middle East and beyond, and will play an important role in promoting new energy mobility and sustainable energy transformation in the UAE and the Middle East. NWTN plans to initially operate the facility for manufacturing, research and development, vehicle testing and logistics area. Since obtaining approval from KEZAD Group for the required modifications and the industrial license in October, NWTN has completed 80% of the equipment installation and tooling in the facility, including the robots used for the vision system and advanced driver assistance systems calibration. The full semi-knock down management and operations team will be in place by the middle of December, 2022, and the facility will be fully operational by the end of this year. The annual capacity of the facility will initially be 5,000-10,000 units for the semi-knock down electric vehicles to meet rapidly increasing demand for new energy vehicles and sustainable transport options in the UAE and in other nations in the Middle East and North Africa. In phase two, NWTN will introduce several new electric vehicle models and expand capacity to 50,000 units annually with an expected start date in the first quarter of 2024.

06:40 EST Axsome Therapeutics says AXS-05 achieves primary endpoint in ACCORD trial - Axsome Therapeutics announced that AXS-05, a novel, oral, investigational NMDA receptor antagonist with multimodal activity, met the primary and key secondary endpoints in the ACCORD Phase 3 trial, by substantially and statistically significantly delaying the time to relapse and preventing relapse of agitation in patients with Alzheimer's disease, as compared to placebo. The ACCORD study was a double-blind, placebo-controlled, multi-center, randomized withdrawal, U.S. trial which treated 178 patients with Alzheimer's disease agitation. Patients achieving a sustained clinical response after open-label treatment with AXS-05 were randomized in a 1:1 ratio to continue treatment with AXS-05 or to discontinue AXS-05 and switch to placebo. AXS-05 has been granted Breakthrough Therapy designation by the U.S. Food and Drug Administration for the treatment of Alzheimer's disease agitation. There are currently no FDA-approved treatments for Alzheimer's disease agitation. AXS-05 met the primary endpoint by substantially and statistically significantly delaying the time to relapse of agitation symptoms as compared to placebo, with a hazard ratio for time to relapse of 0.275, representing a 3.6-fold lower risk of relapse compared to placebo. AXS-05 also met the key secondary endpoint of relapse prevention, based on the rates of relapse during the double-blind treatment period. Relapse was defined as a greater than or equal to10-point worsening in the CMAI total score from randomization or a CMAI total score greater than that at study entry; or hospitalization or other institutionalization due to agitation associated with Alzheimer's disease. With open-label treatment with AXS-05, patients experienced rapid, substantial, and statistically significant improvement compared to baseline in agitation symptoms. Statistically significant improvement on the Cohen Mansfield Agitation Inventory was seen with open-label AXS-05 treatment at all timepoints starting at Week 1, with mean reductions from baseline of 11.0 points at Week 2, and 20.6 points at Week 5. Improvements were also significant with open-label AXS-05 treatment on all CMAI subscales including the Physically Aggressive subscale at all timepoints. Rapid and substantial improvement in Alzheimer's disease agitation was reported by both clinicians and caregivers on global measures. Clinicians reported improvement in agitation in 66.3% of patients at Week 2 and 86.3% at Week 5 after treatment with AXS-05, as assessed using the modified Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change for Agitation. Caregivers reported improvement in agitation in 67.5% of patients at Week 2 and 89.3% at Week 5 after treatment with AXS-05, as assessed using the Patient Global Impression of Change rated by the caregiver. Caregiver distress and burden, patient quality of life, and depressive symptoms were all statistically significantly improved compared to baseline after patients were treated with open-label AXS-05. Caregiver distress was assessed using the NPI Agitation and Aggression Caregiver Distress score. Caregiver burden was assessed using the Zarit Burden Interview. Patient quality of life was assessed using the caregiver rated Quality of Life Alzheimer's Disease scale. Depressive symptoms were assessed using the Cornell Scale for Depression in Dementia. The rates of adverse events observed in the double-blind period were 28.3% in the AXS-05 group and 22.2% in the placebo group. Discontinuations in the double-blind period due to adverse events were low. One serious adverse event was reported in the AXS-05 group, which was determined by the investigator to be not related to study medication, and 2 serious adverse events were reported in the placebo group. Falls were reported in 4 patients in the AXS-05 group, none of which were associated with serious adverse events and all of which were determined by the investigators to be not related to study medication, and in 2 patients in the placebo group, one of which was associated with a femur fracture. One death was reported in the placebo group. There was no evidence of cognitive decline for patients treated with AXS-05 as shown by the Mini-Mental State Examination, a widely utilized measure of general cognitive function. Treatment with AXS-05 was not associated with sedation. AXS-05 was granted Breakthrough Therapy designation for the treatment of Alzheimer's disease agitation by the FDA in June 2020. The FDA Breakthrough Therapy designation was supported by the positive results of the ADVANCE-1 trial. A Breakthrough Therapy designation is granted to potentially expedite development and review timelines for a promising investigational medicine when preliminary clinical evidence indicates it may demonstrate substantial improvement on one or more clinically significant endpoints over available therapies for a serious or life-threatening condition. A total of 178 patients were treated with open-label AXS-05 for up to 9 weeks and assessed for efficacy. The primary timepoint for open-label efficacy assessments was 5 weeks, and the key secondary timepoint was 2 weeks. P-values were calculated versus baseline. The mean CMAI total score was 70.9 at baseline. Treatment with AXS-05 was associated with a mean reduction from baseline in the CMAI total score of 6.7 points at Week 1, 11.0 points at Week 2, and 20.6 points at Week 5. Clinical response on the CMAI after treatment with AXS-05 was achieved by 21.8% of patients at Week 1, 40.4% of patients at Week 2, and 70.0% of patients at Week 5. Treatment with AXS-05 was also associated with improvements on all CMAI subscales including the Physically Aggressive subscale at all timepoints. Improvement in Alzheimer's disease agitation, assessed using the clinician rated mADCS-CGIC, was achieved by 47.1% of patients at Week 1, 66.3% of patients at Week 2, and 86.3% of patients at Week 5, after treatment with AXS-05. Improvement in Alzheimer's disease agitation, assessed using the caregiver rated PGI-C, was achieved by 51.2% of patients at Week 1, 67.5% of patients at Week 2, and 89.3% of patients at Week 5, after treatment with AXS-05. Caregiver distress, assessed using the NPI Agitation and Aggression Caregiver Distress score, was significantly reduced after treatment with AXS-05. Caregiver burden, assessed using the ZBI, was significantly reduced after treatment with AXS-05. Patient quality of life, assessed using the caregiver rated QoL-AD scale, was significantly improved after treatment with AXS-05. Depressive symptoms, assessed using the CSDD, were significantly reduced after treatment with AXS-05. A total of 108 patients were randomized, 53 to continued treatment with AXS-05, and 55 switched to placebo. The mean CMAI total scores at randomization were 43.7 and 44.9 for the AXS-05 and placebo groups respectively. AXS-05 met the primary endpoint by substantially and statistically significantly delaying the time to relapse of Alzheimer's disease agitation as compared to placebo, demonstrating a 3.6-fold lower risk of relapse compared to placebo. AXS-05 met the key secondary endpoint by preventing relapse of Alzheimer's disease agitation as compared to placebo, with 7.5% of AXS-05 patients relapsing versus 25.9% of patients switched to placebo. The rates of adverse events in the double-blind period were 28.3% in the AXS-05 group and 22.2% in the placebo group. Discontinuations in the double-blind period due to adverse events were low.

06:28 EST Philip Morris Holland Holdings becomes owner of 93.11% of Swedish Match shares - On May 11, 2022, Philip Morris Holland Holdings, an affiliate of Philip Morris International (PM), announced a recommended public offer to the shareholders of Swedish Match AB (SWMAY) to tender all shares in Swedish Match to PMHH. On November 7, 2022, PMHH declared the Offer unconditional and announced that it would complete the Offer and acquire all shares in Swedish Match that have been tendered in the Offer. In addition, PMHH extended the acceptance period until November 25, 2022 and informed the Swedish Match shareholders that the price in the Offer for shares tendered during the further extended acceptance period would be reduced to SEK 115.07 in cash per share due to the resolved dividend payment by Swedish Match of SEK 0.93 per share for shareholders of record as of November 14, 2022. Today, PMHH announces that it becomes the owner of 93.11 percent2 of the shares in Swedish Match. The Offer is now closed. The shares tendered in the Offer at the end of the acceptance period amounted to in aggregate 1,255,989,816 shares in Swedish Match, corresponding to approximately 82.59 percent of the share capital and the voting rights in Swedish Match. On November 10, 2022, PMHH announced that PMHH had acquired 49,899,948 shares in Swedish Match outside the Offer, corresponding to approximately 3.28 percent2 of the share capital and the voting rights in Swedish Match, since the announcement of the outcome of the Offer on November 7, 2022. The shares tendered in the Offer during the further extended acceptance period amount to in aggregate 80,933,854 shares in Swedish Match, corresponding to approximately 5.32 percent of the share capital and the voting rights in Swedish Match. In addition, PMHH has acquired an additional 29,164,342 shares in Swedish Match outside the Offer, corresponding to approximately 1.92 percent of the share capital and the voting rights in Swedish Match, since the announcement of the press release on November 10, 2022. No acquisitions have been made at a price exceeding the price in the Offer. Accordingly, the total number of shares in Swedish Match held by PMHH, including the shares tendered in the Offer at the end of the further extended acceptance period on November 25, 2022, amounts to 1,415,987,960 shares, corresponding to approximately 93.11 percent of the share capital and the voting rights in Swedish Match The transaction will result in a combined company with a strong balance sheet and leverage of approximately 3x net debt to adjusted EBITDA, with deleveraging anticipated over the next few years. PMI remains committed to its strong single-A credit ratings, as a growing and highly cash-generative business. To support deleveraging, PMI has suspended its current three-year share repurchase program, which began in July 2021. PMI also remains committed to its progressive dividend policy, while gradually reducing its adjusted diluted EPS payout ratio to around 75% over time. PMHH has decided not to further extend the acceptance period. Settlement for shares tendered in the Offer during the extended acceptance period, is expected to be initiated around December 2, 2022. PMHH reserves the right to postpone the settlement date, provided however, that settlement shall in any event be made within 7 business days following the expiration of the acceptance period. PMHH will announce any postponement of the settlement date by a press release in accordance with applicable laws and regulations PMHH intends to initiate compulsory redemption under the Swedish Companies Act to acquire all remaining shares in Swedish Match. PMHH also intends to request delisting of Swedish Match's shares from Nasdaq Stockholm. Prior to the announcement of the Offer, neither PMHH nor any closely related companies or closely related parties owned or otherwise controlled any shares in Swedish Match or other financial instruments that give financial exposure to Swedish Match's shares. Apart from the 79,064,290 shares in Swedish Match that PMHH has acquired outside the Offer, as described above, neither PMHH or any closely related companies or closely related parties have acquired any shares in Swedish Match or other financial instruments that give financial exposure to Swedish Match's shares outside the Offer. To the extent permissible under applicable law or regulations, PMHH and its affiliates may acquire, or take measures to acquire, additional shares in Swedish Match in other ways than through the Offer. Information about such acquisitions of shares, or measures to acquire shares, will be disclosed in accordance with applicable laws and regulations. Due to the resolved dividend payment by Swedish Match of SEK 0.93 per share with record date for the payment on November 14, 2022, and date for payment through Euroclear Sweden on November 17, 2022, the price in the Offer for shares tendered during the further extended acceptance period has, in accordance with the terms and conditions of the Offer4, been reduced accordingly to SEK 115.07 in cash per share. For further information regarding Swedish Match's resolution on dividends at the annual general meeting 2022, please refer to Swedish Match's website, www.swedishmatch.com. Since the Offer has been declared unconditional, shareholders who have accepted the Offer have no right to withdraw acceptances.

06:15 EST Prime Mining announces assay results from Phase 2 drill program - Prime Mining announces additional assay results from its recently completed Phase 2 drill program. Today's results are from the Guadalupe area where Prime continues to delineate and expand the multi-million-ounce Los Reyes high-grade gold-silver deposit. Los Reyes and its three known gold-silver deposit areas, has a mineralized footprint of over 15 square kilometres and is located in a highly prospective, 500-year old mining-friendly district of Sinaloa, Mexico. Today's results are from seven drill holes in the main Guadalupe deposit. HIGHLIGHT GUADALUPE DRILL INTERCEPTS: 6.8 gpt Au and 166 gpt Ag over 19.5 m in hole 22GE-118; 12.8 gpt Au and 646 gpt Ag over 3.3 m, and 4.2 gpt Au and 212 gpt Ag over 37.2 m in hole 22GE-121; 8.8 gpt Au and 289 gpt Ag over 7.9 m, including 33.2 gpt Au and 1,072 gpt Ag over 2.0 m in drill hole 22GE-122; 6.8 gpt Au and 208 gpt Ag over 13.6 m in hole 22GE-120. Drilling continues to encounter bonanza and high-grade intercepts at Guadalupe with additional remarkable gold and silver values being intercepted in the Estaca Vein. Additionally, outside of the main Estaca Vein, drilling is delineating a cluster of mineralized vein splays within the main Guadalupe deposit. It is anticipated that these results will further expand resources at Guadalupe. CEO Daniel Kunz commented, "We are very excited about the progress we have made in the Phase 2 drill program. Our exploration team has improved the structural modelling demonstrably, which has resulted in a more targeted and accurate drill program. As a result, the number of wide, high-grade intercepts we are seeing in our results has increased. Our recent drilling, specifically at Guadalupe East, has intersected multiple thick, high-grade gold and silver veins. These new veins are increasing the high-grade zones both within and outside of the known mineralized envelope. We will continue to target these high-grade structures as they remain open along strike and at depth. As we work towards delivering a resource estimate in the first half of next year, we are excited about the increasing contribution of these bonanza grade veins at Los Reyes."

06:11 EST Univar confirms preliminary indication of interest from Brenntag - Univar Solutions (UNVR) confirmed that it has received a preliminary indication of interest from Brenntag SE (BNTGY) regarding a potential transaction. "The Company does not intend to make any additional comments regarding this matter unless and until it is appropriate to do so," it said in a statement.

06:09 EST KBR awarded $69.2M Navy task order - KBR announced it has been awarded a $69.2M task order to deliver total life cycle management of critical airborne manned reconnaissance aircraft systems for the Naval Surface Warfare Center Crane and the Naval Air Systems Command E-2/C-2 Airborne Command and Control Program Office. Under the task order, KBR will modify and upgrade legacy technology, while developing and integrating new technology, for aircraft intelligence, surveillance, reconnaissance and targeting systems. The E-2 is the foremost carrier-born aircraft capable of providing early detection of enemy threats and enemy response to carrier operations conducted in accordance with America's declared defense strategy. The work will focus primarily on the E-2D Advanced Hawkeye, with additional support for the E-2C Hawkeye and C-2A Greyhound aircraft.

06:08 EST Ascendant Resources closes $15M financing agreement with Sprott Streaming - Ascendant Resources entered into a $15M metals stream agreement with Sprott Private Resource Streaming and Royalty Corp. for its Lagoa Salgada VMS project located close to Lisbon, Portugal. Proceeds will be used to complete the ongoing 43-101 compliant feasibility study for the Project; advance permitting activities; to fund the last instalment related to the earn-in for an 80% interest in the Project; and general corporate and working capital purposes. The Stream Agreement provides for the sale and delivery to Sprott Streaming of 1.75% of all metals produced from the Project at a rate of 15% of the market price until the delivery of 45,000 gold equivalent ounces, at which point the rate will be increased to 75% of the market price. Ascendant also has the ability to buy down up to 50% of the stream on or before 2 years following the date of commencement of commercial production at the Project for up to $10.5M. To facilitate funding in advance of commercial production, an affiliate of Sprott Streaming issued a $15M secured note that bears interest at a rate of 10% per annum, calculated and payable quarterly and will mature on the earlier of: the achievement of commercial production at the Project together with certain other conditions; and November 25, 2031. Subject to the final approval of the TSX Exchange, the Company may elect to satisfy the payment of any accrued and unpaid interest on the Note by the issuance of common shares of the Company at a price per Common Share equal to 95% of the volume weighted average price of the Common Shares for the 5 trading days immediately prior to the date payment of interest is due or any combination of cash and Common Shares in the Company's sole discretion up to a maximum of 32,617,109 Common Shares. Pledges of shares and intercompany indebtedness were provided by the Company, its wholly owned subsidiary, Ascendant Resources Portugal, Unipessoal LDA, and Redcorp as security for the Note. The Note security is intended to subordinate to future project financing for the Project. The Company has provided Sprott Streaming a first right of approval to participate in any future stream or royalty type financing until certain delivery thresholds are met. Sprott has previously expressed interest in potential additional financing of approximately $60M. The Company also announces that it has amended the terms of the unanimous shareholders agreement with Mineral & Financial Investments to provide, among other things, a right in favour of M&FI such that M&FI may put all, but not less than, of its shares of Redcorp to Ascendant in consideration of an amount, payable in cash, equal to 5% of the post-tax net present value of the Project provided in the feasibility study completed prior to the date of exercise using a 10.5% discount rate.

06:04 EST RadNet's Aidence, Google Health enter collaboration for lung cancer screening - RadNet, Inc. (RDNT) reported that its lung artificial intelligence subsidiary, Aidence, and Google Health, a division of Alphabet, Inc. (GOOG), announced an agreement to license Google Health's AI research model for lung nodule malignancy prediction on CT imaging. Aidence will develop, validate and bring this model to the market to support the early and accurate diagnosis of lung cancer and the reduction of unnecessary procedures in screening programs. Aidence and Google Health intend to complete an AI application for lung nodule malignancy prediction. In this collaboration, Google Health will provide its scientific expertise. Aidence will further develop the model into a solution for clinical practice and bring it to market, complying with relevant data privacy requirements and regulatory standards. The development of this AI application is a statement of intent and no regulatory market applications have been made and no orders for sale are being taken.